REVANCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | +3.34% |
|
-10.05% | -61.32% |
| Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
| Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 821.4 | 1,886 | 1,172 | 1,519 | 771.9 | 354.3 | - | - |
| Enterprise Value (EV) 1 | 531.3 | 1,630 | 1,172 | 1,519 | 1,064 | 663.2 | 583.9 | 567.1 |
| P/E ratio | -4.42 x | -5.83 x | -3.91 x | -3.77 x | -2.3 x | -1.64 x | -3.22 x | -53.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,989 x | 123 x | 15.1 x | 11.5 x | 3.3 x | 1.26 x | 0.92 x | 0.7 x |
| EV / Revenue | 1,286 x | 106 x | 15.1 x | 11.5 x | 4.54 x | 2.36 x | 1.51 x | 1.12 x |
| EV / EBITDA | -3.29 x | -6.2 x | -4.6 x | -4.93 x | -6.65 x | -6.78 x | -83.8 x | 7.48 x |
| EV / FCF | -4.81 x | -8.93 x | -5.05 x | -7.72 x | -4.76 x | -5.19 x | -14.2 x | 12.2 x |
| FCF Yield | -20.8% | -11.2% | -19.8% | -13% | -21% | -19.3% | -7.06% | 8.16% |
| Price to Book | - | - | - | - | -5.1 x | -1.31 x | -1.78 x | -2.07 x |
| Nbr of stocks (in thousands) | 50,608 | 66,549 | 71,795 | 82,274 | 87,813 | 104,216 | - | - |
| Reference price 2 | 16.23 | 28.34 | 16.32 | 18.46 | 8.790 | 3.400 | 3.400 | 3.400 |
| Announcement Date | 2/24/20 | 2/22/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.413 | 15.32 | 77.8 | 132.6 | 234 | 281.5 | 386.1 | 504.9 |
| EBITDA 1 | -161.6 | -262.9 | -254.8 | -308.2 | -160.1 | -97.85 | -6.968 | 75.82 |
| EBIT 1 | -164.5 | -273.2 | -274.7 | -342 | -316.8 | -177.9 | -80.89 | 16.9 |
| Operating Margin | -39,820.58% | -1,782.46% | -353.06% | -257.95% | -135.35% | -63.21% | -20.95% | 3.35% |
| Earnings before Tax (EBT) 1 | -159.4 | -284.7 | -281.3 | -355.7 | -323.7 | -184.8 | -93.61 | 14.11 |
| Net income 1 | -159.4 | -282.1 | -281.3 | -356.4 | -324 | -185.2 | -89.88 | 11.33 |
| Net margin | -38,602.66% | -1,840.71% | -361.59% | -268.87% | -138.43% | -65.8% | -23.28% | 2.24% |
| EPS 2 | -3.670 | -4.860 | -4.170 | -4.900 | -3.830 | -2.070 | -1.057 | -0.0640 |
| Free Cash Flow 1 | -110.5 | -182.6 | -231.9 | -196.8 | -223.5 | -127.8 | -41.25 | 46.3 |
| FCF margin | -26,766.59% | -1,191.52% | -298.1% | -148.42% | -95.48% | -45.4% | -10.68% | 9.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 61.06% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 408.6% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/22/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19.74 | 25.95 | 25.26 | 28.37 | 29.02 | 49.92 | 49.33 | 58.13 | 56.78 | 69.8 | 56.66 | 68.19 | 69.67 | 85.28 | 79.4 |
| EBITDA | -67.57 | -56.18 | -56.84 | -52.39 | -72.04 | -126.9 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -72.72 | -61.6 | -62.22 | -57.84 | -77.48 | -144.4 | -58.03 | -65.5 | -139.3 | -53.95 | -68.78 | -42.17 | -40.4 | -27.43 | - |
| Operating Margin | -368.31% | -237.39% | -246.31% | -203.9% | -267.05% | -289.28% | -117.64% | -112.67% | -245.34% | -77.3% | -121.39% | -61.85% | -58% | -32.16% | - |
| Earnings before Tax (EBT) 1 | -74.38 | -63.1 | -64.34 | -61.44 | -83.99 | -146 | -59.79 | -67.32 | -140.9 | -55.7 | -70.29 | -44.14 | -42.45 | -29.59 | - |
| Net income 1 | -74.38 | -63.1 | -64.34 | -61.44 | -84.69 | -146 | -59.79 | -67.32 | -141.2 | -55.7 | -70.29 | -44.14 | -42.45 | -29.59 | - |
| Net margin | -376.68% | -243.15% | -254.71% | -216.56% | -291.89% | -292.37% | -121.21% | -115.8% | -248.65% | -79.8% | -124.07% | -64.74% | -60.94% | -34.7% | - |
| EPS 2 | -1.100 | -0.9300 | -0.9400 | -0.8800 | -1.170 | -1.900 | -0.7400 | -0.8000 | -1.630 | -0.6200 | -0.7160 | -0.5060 | -0.4800 | -0.3740 | -0.4900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/10/22 | 8/9/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/8/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 292 | 309 | 230 | 213 |
| Net Cash position 1 | 290 | 256 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -1.823 x | -3.156 x | -32.95 x | 2.806 x |
| Free Cash Flow 1 | -111 | -183 | -232 | -197 | -223 | -128 | -41.3 | 46.3 |
| ROE (net income / shareholders' equity) | - | - | - | -879% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | -1.720 | -2.600 | -1.920 | -1.640 |
| Cash Flow per Share | - | - | - | -2.660 | -2.560 | - | - | - |
| Capex 1 | 3.24 | 4.1 | 10.4 | 3.21 | 6.89 | 7.5 | 8.75 | 9.75 |
| Capex / Sales | 784.02% | 26.74% | 13.34% | 2.42% | 2.94% | 2.66% | 2.27% | 1.93% |
| Announcement Date | 2/24/20 | 2/22/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
3.4
USD
Average target price
16.33
USD
Spread / Average Target
+380.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -61.32% | 354M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- RVNC Stock
- Financials Revance Therapeutics, Inc.
